Editorial comment on: Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.
作者信息
Montironi Rodolfo, Lopez-Beltran Antonio, Cheng Liang
出版信息
Eur Urol. 2008 Oct;54(4):843-4. doi: 10.1016/j.eururo.2007.12.027. Epub 2007 Dec 26.
PMID:18166261
Abstract
摘要
相似文献
1
Editorial comment on: Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.关于《WHO 1973年和2004年分级及FGFR3突变状态对非肌层浸润性膀胱癌进展的预测：一项前瞻性研究》的编辑评论
Eur Urol. 2008 Oct;54(4):843-4. doi: 10.1016/j.eururo.2007.12.027. Epub 2007 Dec 26.
2
Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.通过WHO 1973年和2004年分级以及FGFR3突变状态预测非肌层浸润性膀胱癌的进展：一项前瞻性研究。
Eur Urol. 2008 Oct;54(4):835-43. doi: 10.1016/j.eururo.2007.12.026. Epub 2007 Dec 26.
3
Editorial comment on: FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.关于“FGFR3突变提示浸润性上尿路及膀胱肿瘤患者预后更佳”的编辑评论
Eur Urol. 2009 Mar;55(3):658. doi: 10.1016/j.eururo.2008.06.015. Epub 2008 Jun 13.
4
Editorial comment on: FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.关于《FGFR3突变提示浸润性上尿路和膀胱肿瘤患者有更好的生存率》的编辑评论
Eur Urol. 2009 Mar;55(3):657. doi: 10.1016/j.eururo.2008.06.014. Epub 2008 Jun 13.
5
FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.FGFR3突变表明侵袭性上尿路和膀胱肿瘤患者的生存率更高。
Eur Urol. 2009 Mar;55(3):650-7. doi: 10.1016/j.eururo.2008.06.013. Epub 2008 Jun 13.
6
CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.CDKN2A 纯合缺失与 FGFR3 突变型尿路上皮膀胱癌的肌肉浸润有关。
J Pathol. 2012 Jul;227(3):315-24. doi: 10.1002/path.4017. Epub 2012 May 8.
7
FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.T1G3期移行性膀胱癌中FGFR3和Tp53突变：独立分布及与预后无关
Clin Cancer Res. 2005 Aug 1;11(15):5444-50. doi: 10.1158/1078-0432.CCR-05-0122.
8
Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.膀胱癌中成纤维细胞生长因子受体3基因（FGFR3）A248C、S249C、G372C和T375C突变的发生率。
Genet Mol Res. 2011 Jan 18;10(1):86-95. doi: 10.4238/vol10-1gmr923.
9
10
Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.利用成纤维细胞生长因子受体3和MIB-1对尿路上皮细胞癌进行分子分级在预测临床结局方面优于病理分级。
J Clin Oncol. 2003 May 15;21(10):1912-21. doi: 10.1200/JCO.2003.05.073.
引用本文的文献
1
Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor Receptor.尿路上皮膀胱癌：成纤维细胞生长因子受体的基因组改变。
Mol Diagn Ther. 2023 Jul;27(4):475-485. doi: 10.1007/s40291-023-00647-0. Epub 2023 May 17.
2
MCM2 and MCM5 as prognostic markers in colon cancer: a worthwhile approach.
Dig Dis Sci. 2009 Feb;54(2):197-8. doi: 10.1007/s10620-008-0416-6. Epub 2008 Aug 21.
Zotero 插件